Published in Gastroenterology on August 14, 2007
Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol Int (2008) 5.25
KASL Clinical Practice Guidelines: Management of chronic hepatitis B. Clin Mol Hepatol (2012) 2.10
First-line treatment of chronic hepatitis B with entecavir or tenofovir in 'real-life' settings: from clinical trials to clinical practice. J Viral Hepat (2012) 1.38
Identification of disubstituted sulfonamide compounds as specific inhibitors of hepatitis B virus covalently closed circular DNA formation. Antimicrob Agents Chemother (2012) 1.31
Why are there different dynamics in the selection of drug resistance in HIV and hepatitis B and C viruses? J Antimicrob Chemother (2008) 1.21
HBeAg seroconversion as an important end point in the treatment of chronic hepatitis B. Hepatol Int (2009) 1.13
Management of chronic hepatitis B infection: current treatment guidelines, challenges, and new developments. World J Gastroenterol (2014) 1.10
Hepatitis B e antigen seroconversion: a critical event in chronic hepatitis B virus infection. Dig Dis Sci (2010) 1.07
Chronic hepatitis B: whom to treat and for how long? Propositions, challenges, and future directions. Hepatol Int (2010) 1.03
Long-term nucleos(t)ide analogues therapy for adults with chronic hepatitis B reduces the risk of long-term complications: a meta-analysis. Virol J (2011) 1.01
Lamivudine plus adefovir combination therapy versus entecavir monotherapy for lamivudine-resistant chronic hepatitis B: a systematic review and meta-analysis. Virol J (2011) 1.00
Safety and efficacy of entecavir for the treatment of chronic hepatitis B. Infect Drug Resist (2011) 0.99
Current Antiviral Therapy of Chronic Hepatitis B: Efficacy and Safety. Curr Hepat Rep (2011) 0.99
Impact of viral replication inhibition by entecavir on peripheral T lymphocyte subpopulations in chronic hepatitis B patients. BMC Infect Dis (2008) 0.98
The Roadmap concept: using early on-treatment virologic responses to optimize long-term outcomes for patients with chronic hepatitis B. Hepatol Int (2008) 0.98
Current Nucleos(t)ide Analogue Therapy for Chronic Hepatitis B. Gut Liver (2011) 0.97
Correlation between hepatitis B surface antigen titers and HBV DNA levels. Saudi J Gastroenterol (2013) 0.96
Enhancing the antihepatitis B virus immune response by adefovir dipivoxil and entecavir therapies. Cell Mol Immunol (2010) 0.94
Antiviral therapies and prospects for a cure of chronic hepatitis B. Cold Spring Harb Perspect Med (2015) 0.93
Core protein: A pleiotropic keystone in the HBV lifecycle. Antiviral Res (2015) 0.93
Similar response to entecavir 0.5 and 1.0 mg in treatment-naïve chronic hepatitis B patients: a case-control study. Dig Dis Sci (2013) 0.92
Virologic, serologic, and biochemical outcomes through 2 years of treatment with entecavir and lamivudine in nucleoside-naïve Chinese patients with chronic hepatitis B: a randomized, multicenter study. Hepatol Int (2008) 0.91
Management of chronic hepatitis B with nucleoside or nucleotide analogues: a review of current guidelines. Gut Liver (2010) 0.90
Efficacy and resistance of entecavir following 3 years of treatment of Japanese patients with lamivudine-refractory chronic hepatitis B. Hepatol Int (2010) 0.87
DNA-guided hepatitis B treatment, viral load is essential, but not sufficient. World J Gastroenterol (2009) 0.87
Recent advances in the management of chronic hepatitis B. Hepat Mon (2011) 0.87
A Systematic Review of Side Effects of Nucleoside and Nucleotide Drugs Used for Treatment of Chronic Hepatitis B. Curr Hepat Rep (2010) 0.86
Comparison of the Effects of Telbivudine and Entecavir Treatment on Estimated Glomerular Filtration Rate in Patients with Chronic Hepatitis B. Gut Liver (2015) 0.86
Efficacy of entecavir and adefovir combination therapy for patients with lamivudine- and entecavir-resistant chronic hepatitis B. Dig Dis Sci (2011) 0.86
Off-treatment virologic relapse and outcomes of re-treatment in chronic hepatitis B patients who achieved complete viral suppression with oral nucleos(t)ide analogs. BMC Infect Dis (2014) 0.86
Current and future directions for treating hepatitis B virus infection. World J Hepatol (2015) 0.85
Antiviral therapy for chronic hepatitis B in China. Med Microbiol Immunol (2014) 0.85
Treatment of chronic hepatitis B in clinical practice with entecavir or tenofovir. World J Gastroenterol (2014) 0.85
Durability of Hepatitis B e Antigen Seroconversion in Chronic Hepatitis B Patients Treated with Entecavir or Tenofovir. Dig Dis Sci (2015) 0.83
Systematic review of the literature on comparative effectiveness of antiviral treatments for chronic hepatitis B infection. J Gen Intern Med (2011) 0.82
Long-term treatment outcomes of clevudine in antiviral-naive patients with chronic hepatitis B. World J Gastroenterol (2012) 0.81
Outcome of various treatments for posttransplant hepatitis B virus recurrence. World J Surg (2013) 0.81
Current status of antiviral therapy for hepatitis B. Therap Adv Gastroenterol (2008) 0.81
Current therapeutic strategies for recurrent hepatitis B virus infection after liver transplantation. World J Gastroenterol (2010) 0.80
On-treatment monitoring of HBV DNA levels: predicting response and resistance to oral antiviral therapy at week 24 versus week 48. Hepatol Int (2009) 0.80
Long-term real-world entecavir therapy in treatment-naïve hepatitis B patients: base-line hepatitis B virus DNA and hepatitis B surface antigen levels predict virologic response. Korean J Intern Med (2016) 0.79
Hepatitis B virus management to prevent reactivation after chemotherapy: a review. Support Care Cancer (2012) 0.79
Hepatitis B Virus Reactivation during Treatment with Multi-Tyrosine Kinase Inhibitor for Hepatocellular Carcinoma. Case Rep Oncol (2012) 0.79
Hepatitis B virus infection and renal transplantation. World J Gastroenterol (2010) 0.79
Pros and Cons of Peginterferon Versus Nucleos(t)ide Analogues for Treatment of Chronic Hepatitis B. Curr Hepat Rep (2010) 0.79
Two cases of development of entecavir resistance during entecavir treatment for nucleoside-naive chronic hepatitis B. Hepatol Int (2008) 0.79
A novel estimation of the relative economic value in terms of different chronic hepatitis B treatment options. PLoS One (2013) 0.79
The Discovery and Development of a Potent Antiviral Drug, Entecavir, for the Treatment of Chronic Hepatitis B. J Clin Transl Hepatol (2013) 0.78
Current prophylactic strategies against hepatitis B virus recurrence after liver transplantation. World J Gastroenterol (2009) 0.78
Long-term effects of lamivudine treatment in Japanese chronic hepatitis B patients. World J Gastroenterol (2011) 0.78
Pretreatment serum HBsAg-to-HBV DNA ratio predicts a virologic response to entecavir in chronic hepatitis B. Korean J Hepatol (2011) 0.78
The saga of entecavir. Hepatol Int (2009) 0.77
Tenofovir-based alternate therapies for chronic hepatitis B patients with partial virological response to entecavir. J Viral Hepat (2014) 0.77
HBV and HCV therapy. Viruses (2009) 0.76
Unsuccessful therapy with adefovir and entecavir-tenofovir in a patient with chronic hepatitis B infection with previous resistance to lamivudine: a fourteen-year evolution of hepatitis B virus mutations. BMC Infect Dis (2011) 0.76
Future aspects of therapy for hepatitis B virus infection: value of surrogate markers, innovative therapy, and global collaboration. J Gastroenterol (2011) 0.76
Telbivudine versus entecavir in patients with undetectable hepatitis B virus DNA: a randomized trial. BMC Gastroenterol (2017) 0.75
UGT2B28 genomic variation is associated with hepatitis B e-antigen seroconversion in response to antiviral therapy. Sci Rep (2016) 0.75
Hepatitis B: explosion of new knowledge. Gastroenterology (2007) 0.75
Dry Blood Spots a Reliable Method for Measurement of Hepatitis B Viral Load in Resource-Limited Settings. PLoS One (2016) 0.75
HBeAg Seroconversion in HBeAg-Positive Chronic Hepatitis B Patients Receiving Long-Term Nucleos(t)ide Analog Treatment: A Systematic Review and Network Meta-Analysis. PLoS One (2017) 0.75
Comparison of the clinical outcomes between antiviral-naïve patients treated with entecavir and lamivudine-resistant patients receiving adefovir add-on lamivudine combination treatment. Clin Mol Hepatol (2016) 0.75
Efficacy of Real-world Entecavir Therapy in Treatment-naïve Chronic Hepatitis B Patients. Chin Med J (Engl) (2017) 0.75
Guideline of Prevention and Treatment for Chronic Hepatitis B (2015 Update). J Clin Transl Hepatol (2017) 0.75
Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon. N Engl J Med (2008) 9.33
Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med (2014) 9.25
A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med (2006) 7.35
Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med (2008) 7.22
Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med (2003) 5.97
Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med (2006) 5.65
Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol Int (2008) 5.25
Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma. Gastroenterology (2009) 4.50
Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment. Gastroenterology (2004) 4.27
Genetic diversity of hepatitis B virus strains derived worldwide: genotypes, subgenotypes, and HBsAg subtypes. Intervirology (2004) 4.12
Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N Engl J Med (2003) 4.12
Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naïve patients is rare through 5 years of therapy. Hepatology (2009) 4.00
Prognosis of hepatocellular carcinoma: comparison of 7 staging systems in an American cohort. Hepatology (2005) 3.95
Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology (2006) 3.80
A systematic review of hepatitis C virus epidemiology in Asia, Australia and Egypt. Liver Int (2011) 3.69
Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B. Hepatology (2010) 3.57
Coffee intake is associated with lower rates of liver disease progression in chronic hepatitis C. Hepatology (2009) 3.50
Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B. N Engl J Med (2005) 3.46
Evolution of the HALT-C Trial: pegylated interferon as maintenance therapy for chronic hepatitis C in previous interferon nonresponders. Control Clin Trials (2004) 3.46
Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study. J Clin Oncol (2013) 3.45
Detection of hepatocellular carcinoma at advanced stages among patients in the HALT-C trial: where did surveillance fail? Am J Gastroenterol (2013) 3.41
Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet (2005) 3.33
Risk estimation for hepatocellular carcinoma in chronic hepatitis B (REACH-B): development and validation of a predictive score. Lancet Oncol (2011) 3.32
Eltrombopag before procedures in patients with cirrhosis and thrombocytopenia. N Engl J Med (2012) 3.20
Alcohol, tobacco and obesity are synergistic risk factors for hepatocellular carcinoma. J Hepatol (2005) 3.18
Long-term efficacy of tenofovir monotherapy for hepatitis B virus-monoinfected patients after failure of nucleoside/nucleotide analogues. Hepatology (2010) 3.02
NAFLD may be a common underlying liver disease in patients with hepatocellular carcinoma in the United States. Hepatology (2002) 2.96
A small molecule HIV-1 inhibitor that targets the HIV-1 envelope and inhibits CD4 receptor binding. Proc Natl Acad Sci U S A (2003) 2.92
GP73, a resident Golgi glycoprotein, is a novel serum marker for hepatocellular carcinoma. J Hepatol (2005) 2.70
Identification of hepatitis C virus NS5A inhibitors. J Virol (2010) 2.58
Effectiveness of hepatocellular carcinoma surveillance in patients with cirrhosis. Cancer Epidemiol Biomarkers Prev (2012) 2.57
Risk factors for early and late recurrence in hepatitis B-related hepatocellular carcinoma. J Hepatol (2009) 2.56
Hospital readmissions among patients with decompensated cirrhosis. Am J Gastroenterol (2011) 2.49
Lanreotide reduces the volume of polycystic liver: a randomized, double-blind, placebo-controlled trial. Gastroenterology (2009) 2.33
Outcomes of living donor liver transplantation for acute liver failure: the adult-to-adult living donor liver transplantation cohort study. Liver Transpl (2008) 2.30
Concurrent chemoradiotherapy treatment of locally advanced pancreatic cancer: gemcitabine versus 5-fluorouracil, a randomized controlled study. Int J Radiat Oncol Biol Phys (2003) 2.25
Hepatitis B therapy. Nat Rev Gastroenterol Hepatol (2011) 2.23
Entecavir for treatment of lamivudine-refractory, HBeAg-positive chronic hepatitis B. Gastroenterology (2006) 2.22
Renal failure in patients with hepatocellular carcinoma and ascites undergoing transarterial chemoembolization. Liver Int (2009) 2.09
Prognostic significance of vascular endothelial growth factor, basic fibroblast growth factor, and angiogenin in patients with resectable hepatocellular carcinoma after surgery. Ann Surg Oncol (2003) 2.08
Randomized controlled trial of entecavir prophylaxis for rituximab-associated hepatitis B virus reactivation in patients with lymphoma and resolved hepatitis B. J Clin Oncol (2013) 2.08
First identification of a patient colonized with Klebsiella pneumoniae carrying blaNDM-1 in Taiwan. J Chin Med Assoc (2010) 2.05
Des-gamma carboxyprothrombin can differentiate hepatocellular carcinoma from nonmalignant chronic liver disease in american patients. Hepatology (2003) 2.05
CD73 (ecto-5'-nucleotidase) hepatocyte levels differ across mouse strains and contribute to mallory-denk body formation. Hepatology (2013) 2.04
One-year intense nutritional counseling results in histological improvement in patients with non-alcoholic steatohepatitis: a pilot study. Am J Gastroenterol (2005) 2.04
Modified Charlson comorbidity index for predicting survival after liver transplantation. Liver Transpl (2007) 1.96
Development of a cell-based high-throughput specificity screen using a hepatitis C virus-bovine viral diarrhea virus dual replicon assay. Antimicrob Agents Chemother (2005) 1.94
Treatment of hepatitis B e antigen positive chronic hepatitis with telbivudine or adefovir: a randomized trial. Ann Intern Med (2007) 1.92
Cytochrome P450 2E1 genotype and the susceptibility to antituberculosis drug-induced hepatitis. Hepatology (2003) 1.92
Validation of a liver adenoma classification system in a tertiary referral centre: implications for clinical practice. J Hepatol (2010) 1.91
Risk assessment of hepatitis B virus-related hepatocellular carcinoma development using liver stiffness measurement (FibroScan). Hepatology (2011) 1.87
Recent US Food and Drug Administration warnings on hepatitis B reactivation with immune-suppressing and anticancer drugs: just the tip of the iceberg? Hepatology (2015) 1.87
Liver transplantation: the last measure in the treatment of bile duct injuries. World J Surg (2008) 1.84
Hepatitis C virus infection and the development of type 2 diabetes in a community-based longitudinal study. Am J Epidemiol (2007) 1.83
Peginterferon alfa-2a plus ribavirin for the treatment of dual chronic infection with hepatitis B and C viruses. Gastroenterology (2008) 1.81
Weight-related effects on disease progression in the hepatitis C antiviral long-term treatment against cirrhosis trial. Gastroenterology (2009) 1.80
Tenofovir disoproxil fumarate (TDF), emtricitabine/TDF, and entecavir in patients with decompensated chronic hepatitis B liver disease. Hepatology (2010) 1.79
A new class of retroviral and satellite encoded small RNAs emanates from mammalian centromeres. Chromosoma (2008) 1.79
Psychogenic polydipsia review: etiology, differential, and treatment. Curr Psychiatry Rep (2007) 1.79
Antibiotic prophylaxis after endoscopic therapy prevents rebleeding in acute variceal hemorrhage: a randomized trial. Hepatology (2004) 1.78
A new prognostic model for hepatocellular carcinoma based on total tumor volume: the Taipei Integrated Scoring System. J Hepatol (2010) 1.77
Hepatitis E virus: an underestimated opportunistic pathogen in recipients of allogeneic hematopoietic stem cell transplantation. Blood (2013) 1.77
Liver transplantation for erythropoietic protoporphyria liver disease. Liver Transpl (2005) 1.76
SNIP1 is a candidate modifier of the transcriptional activity of c-Myc on E box-dependent target genes. Mol Cell (2006) 1.73
A prospective, randomized trial of endoscopic hemoclip versus heater probe thermocoagulation for peptic ulcer bleeding. Am J Gastroenterol (2002) 1.73
Energy determinants GAPDH and NDPK act as genetic modifiers for hepatocyte inclusion formation. J Cell Biol (2011) 1.72
Entecavir shows limited efficacy in HBeAg-positive hepatitis B patients with a partial virologic response to adefovir therapy. J Hepatol (2008) 1.71
[Measurement of hepatic venous pressure gradient in liver cirrhosis: relationship with the status of cirrhosis, varices, and ascites in Korea]. Korean J Hepatol (2008) 1.70
Number of target lesions for EASL and modified RECIST to predict survivals in hepatocellular carcinoma treated with chemoembolization. Clin Cancer Res (2012) 1.67
Model for end-stage liver disease score to serum sodium ratio index as a prognostic predictor and its correlation with portal pressure in patients with liver cirrhosis. Liver Int (2007) 1.66
Smoking and alanine aminotransferase levels in hepatitis C virus infection: implications for prevention of hepatitis C virus progression. Arch Intern Med (2002) 1.66
Risk factors for hepatocellular carcinoma may impair the performance of biomarkers: a comparison of AFP, DCP, and AFP-L3. Cancer Biomark (2007) 1.65
Long-term efficacy and safety of adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. Hepatology (2008) 1.65
Polymorphism of the N-acetyltransferase 2 gene as a susceptibility risk factor for antituberculosis drug-induced hepatitis. Hepatology (2002) 1.64
Differential mechanism and prognostic impact of diabetes mellitus on patients with hepatocellular carcinoma undergoing surgical and nonsurgical treatment. Am J Gastroenterol (2004) 1.63
The accuracy of noninvasive methods in predicting the development of hepatocellular carcinoma and hepatic decompensation in patients with chronic hepatitis B. J Clin Gastroenterol (2012) 1.63
Efficacy of entecavir in chronic hepatitis B patients with mildly elevated alanine aminotransferase and biopsy-proven histological damage. Hepatology (2010) 1.61
Sustained virologic response to therapy of recurrent hepatitis C after liver transplantation is related to early virologic response and dose adherence. Liver Transpl (2007) 1.61
Correlation and comparison of the model for end-stage liver disease, portal pressure, and serum sodium for outcome prediction in patients with liver cirrhosis. J Clin Gastroenterol (2007) 1.60
Long-term treatment with entecavir induces reversal of advanced fibrosis or cirrhosis in patients with chronic hepatitis B. Clin Gastroenterol Hepatol (2010) 1.60
Long-term follow-up of alpha-interferon treatment of patients with chronic hepatitis B. Hepatology (2004) 1.59
The Global Rating Scale in clinical practice: a comprehensive quality assurance programme for endoscopy departments. Dig Liver Dis (2012) 1.59
Increased incidence of early de novo cancer in liver graft recipients treated with cyclosporine: an association with C2 monitoring and recipient age. Liver Transpl (2010) 1.59
Cost-effectiveness of peginterferon alpha-2a compared to lamivudine treatment in patients with hepatitis B e antigen positive chronic hepatitis B in Taiwan. J Gastroenterol Hepatol (2007) 1.58
A nationwide seroepidemiology of hepatitis C virus infection in South Korea. Liver Int (2013) 1.57
A randomized trial of endoscopic treatment of acute gastric variceal hemorrhage: N-butyl-2-cyanoacrylate injection versus band ligation. Hepatology (2006) 1.57
Is the corrected-creatinine model for end-stage liver disease a feasible strategy to adjust gender difference in organ allocation for liver transplantation? Transplantation (2007) 1.56
Natural history of hepatitis B virus-related cirrhotic patients hospitalized to control ascites. J Gastroenterol Hepatol (2008) 1.55
Spinal microglia initiate and maintain hyperalgesia in a rat model of chronic pancreatitis. Gastroenterology (2011) 1.55